Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Otezla Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 2002-A

    Specialty Guideline Management Otezla-Otezla XR

    Customize your policy alerts

    Sign up for cvs_caremark Policy 2002-A alerts

    Get alerted when Policy 2002-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Otezla (apremilast) and Otezla XR (apremilast extended-release) for plaque psoriasis, psoriatic arthritis, Behcet's disease, and immune checkpoint inhibitor-related toxicity. It applies to members whose requested therapy meets the applicable indication, prior-treatment, clinical-response, documentation, and prescriber-specialty requirements.

    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Otezla-Otezla XR
    Policy CodePolicy 2002-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit chart notes, medical record documentation, or claims history supporting previous medications tried for initial requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Products covered
    12 monthsAuthorization duration
    4FDA-approved indication categories
    1Compendial-use categories

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not allowed
    Same-indication concomitant therapy

    Coverage Criteria

    Plaque Psoriasis Initial Therapy

    Covered when the member meets the age, diagnosis, and one qualifying treatment pathway below. Submit chart notes, medical records, or claims history documenting prior therapy, response, intolerance, or clinical reasons to avoid therapy.

    Required criteria

    • Qualifying treatment pathway

      • Prior or alternative therapy

        • Member has previously received a biologic or targeted synthetic drug indicated for plaque psoriasis.
        • Member has had an inadequate response or intolerance to phototherapy or topical therapies.

          Phototherapy includes UVB or PUVA. Topical therapies include medium- or higher-potency corticosteroids, calcineurin inhibitors, or vitamin D analogs.

        • Member has a contraindication or clinical reason to avoid both phototherapy and topical therapies.
        • Member has had an inadequate response or intolerance to methotrexate, cyclosporine, or acitretin.
        • Member has a clinical reason to avoid methotrexate, cyclosporine, and acitretin.

    Psoriatic Arthritis Initial Therapy

    Covered when the member meets the age, active-disease, and one qualifying treatment pathway below. Submit documentation of prior treatment, response, intolerance, contraindication, or enthesitis, as applicable.

    Required criteria

    • Qualifying treatment pathway

      • Member has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis.
      • Member has had an inadequate response to methotrexate, leflunomide, or another conventional synthetic drug administered at an adequate dose and duration.

        Another conventional synthetic drug may include sulfasalazine.

      • Member has an intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug.
      • Member has enthesitis.

    Behcet's Disease Initial Therapy

    Covered for an adult member with oral ulcers associated with Behcet's disease when one qualifying treatment pathway is documented. Submit documentation of previous medications tried and response when applicable.

    Required criteria

    • Qualifying treatment pathway

      • Member has previously received a biologic indicated for treatment of Behcet's disease.
      • Member has had an inadequate response to at least one nonbiologic medication for Behcet's disease.At least 1 nonbiologic medication

        Examples include colchicine, systemic glucocorticoids, and azathioprine.

    Immune Checkpoint Inhibitor-Related Toxicity Initial Therapy

    Covered when the member has a qualifying immune checkpoint inhibitor-related condition and meets the applicable treatment or diagnostic pathway. Document the condition, severity, and treatment history.

    Required criteria

    • Qualifying condition and pathway

      • Member has moderate to severe immunotherapy-related psoriasis or psoriasiform disease and has had an inadequate response to high-potency topical corticosteroids.Moderate to severe disease
      • Member has moderate to severe immunotherapy-related psoriasis or psoriasiform disease and has an intolerance or contraindication to high-potency topical corticosteroids.Moderate to severe disease
      • Member has moderate or severe immunotherapy-related inflammatory arthritis with symptoms suggestive of psoriatic arthritis or spondyloarthropathies.

    Plaque Psoriasis Continuation

    Covered for continuation when all of the following are met. Submit chart notes or medical records documenting response from baseline.

    Required criteria

    • Response evidence

      • Reduction in body surface area affected from baseline.Reduction from baseline
      • Improvement from baseline in signs or symptoms such as itching, redness, flaking, scaling, burning, cracking, or pain.Improvement from baseline

    Psoriatic Arthritis Continuation

    Covered for continuation when all of the following are met. Submit documentation of the covered indication and improvement from baseline in at least one disease measure.

    Required criteria

    • Response evidence

      • Improvement from baseline in at least one of the following: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement, functional status, or C-reactive protein.Improvement from baseline in >= 1 measure

    Behcet's Disease Continuation

    Covered for continuation when the adult member achieves or maintains a positive clinical response. Submit documentation of response, including low disease activity or improvement in signs and symptoms.

    Required criteria: Adult member, including a new member, is using the requested medication for Behcet's disease and achieves or maintains low disease activity or improvement in signs and symptoms.Adult member; authorization period = 12 months

    Psoriatic Arthritis Continuation Therapy

    Continuation authorization may be granted when all required conditions are met.

    All criteria

    • Positive clinical response

      • Improvement from baseline in at least one measure: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement, functional status, or C-reactive protein.Improvement from baseline in >= 1 measure

    Behcet's Disease Continuation Therapy

    Continuation authorization may be granted when all required conditions are met.

    All criteria

    • Positive clinical response

      • Member has low disease activity or improvement in signs and symptoms of Behcet's disease.Low disease activity or improvement in signs and symptoms

    Immune Checkpoint Inhibitor-Related Toxicity Continuation Therapy

    Continuation authorization may be granted when all required conditions are met.

    All criteria

    • Covered condition and response

      • Member has low disease activity or improvement in signs and symptoms of immunotherapy-related psoriasis or psoriasiform diseases.
      • Member has low disease activity or improvement in signs and symptoms of immunotherapy-related inflammatory arthritis suggestive of psoriatic arthritis or spondyloarthropathies.

    Coverage applies to Otezla and Otezla XR for the listed FDA-approved indications: adult plaque psoriasis in members who are candidates for phototherapy or systemic therapy; moderate to severe plaque psoriasis in pediatric members 6 years of age and older who meet the applicable weight threshold and are candidates for phototherapy or systemic therapy; active psoriatic arthritis in adults and eligible pediatric members 6 years of age and older; and oral ulcers associated with Behcet's disease in adults. Coverage also includes the compendial use of these products for immune checkpoint inhibitor-related toxicity.

    For any covered indication, the requested medication cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    Indications other than the listed FDA-approved indications and the compendial use of immune checkpoint inhibitor-related toxicity are considered experimental/investigational and not medically necessary.

    Age and Product Requirements

    Pediatric age requirement
    Minimum age6 years of age and older
    Applicable indicationsModerate to severe plaque psoriasis and active psoriatic arthritis
    Otezla pediatric weight requirementAt least 20 kg
    Otezla XR pediatric weight requirementAt least 50 kg
    Otezla pediatric weight requirement
    Minimum age6 years of age and older
    Minimum body weightAt least 20 kg

    Provider Requirements and Authorization Guidance

    Documentation Required

    Required Prescriber Specialty

    The medication must be prescribed by or in consultation with the designated specialist for the requested indication.

    • Plaque psoriasis: dermatologist
    • Psoriatic arthritis: rheumatologist or dermatologist
    • Behcet's disease: rheumatologist
    • Immune checkpoint inhibitor-related toxicity: dermatologist, rheumatologist, hematologist, or oncologist
    Prior Authorization

    Psoriatic Arthritis Continuation

    For psoriatic arthritis, authorization for 12 months may be granted to members age 6 years and older, including new members, when the requested medication is used for psoriatic arthritis and the member achieves or maintains a positive clinical response evidenced by low disease activity or improvement in signs and symptoms.

    Policy Background

    Otezla and Otezla XR are apremilast products used for inflammatory dermatologic and rheumatologic conditions. This policy addresses plaque psoriasis, active psoriatic arthritis, oral ulcers associated with Behcet's disease, and immune checkpoint inhibitor-related toxicity. Initial coverage generally requires qualifying prior treatment, intolerance, contraindication, or another specified clinical pathway; continuation requires evidence of a positive clinical response.

    Initial Therapy by Indication

    Plaque Psoriasis — Initial Therapy Indication

    The plaque psoriasis initial-therapy indication branch applies when the member meets the age requirement and at least one qualifying prior-treatment or avoidance pathway.

    Plaque psoriasis indication branch

    • Qualifying pathway

      • Previous biologic or targeted synthetic drug indicated for plaque psoriasis.
      • Inadequate response or intolerance to phototherapy or topical therapies.
      • Contraindication or clinical reason to avoid both phototherapy and topical therapies.
      • Inadequate response or intolerance to methotrexate, cyclosporine, or acitretin.

    Continuation Therapy by Indication

    Plaque Psoriasis — Continuation Therapy Criteria

    Continuation authorization may be granted when the member meets all of the following criteria.

    Plaque psoriasis continuation

    • Response evidence

      • Reduction in body surface area affected from baseline.
      • Improvement from baseline in signs and symptoms such as itching, redness, flaking, scaling, burning, cracking, or pain.

    Psoriatic Arthritis — Continuation Therapy Criteria

    Continuation authorization may be granted when the member meets all of the following criteria.

    Psoriatic arthritis continuation

    • Response evidence

    Step Therapy Requirements

    StepRequired treatment or evaluationQualifying pathway
    1Biologic or targeted synthetic drug indicated for plaque psoriasis; phototherapy such as UVB or PUVA; topical therapy such as medium- or higher-potency corticosteroids, calcineurin inhibitors, or vitamin D analogs; or pharmacologic therapy with methotrexate, cyclosporine, or acitretin.Previous biologic or targeted synthetic therapy; inadequate response or intolerance to one phototherapy or topical therapy; clinical reason to avoid both phototherapy and topical therapy; inadequate response or intolerance to one of methotrexate, cyclosporine, or acitretin; or clinical reason to avoid all three conventional therapies.
    StepRequired treatment or evaluationQualifying pathway
    1Biologic or targeted synthetic drug indicated for active psoriatic arthritis; methotrexate, leflunomide, or another conventional synthetic drug such as sulfasalazine.Previous biologic or targeted synthetic therapy; inadequate response to a conventional synthetic drug administered at an adequate dose and duration; intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug; or enthesitis.
    StepRequired treatment or evaluationQualifying pathway
    1A biologic indicated for Behcet's disease or at least one nonbiologic medication, such as colchicine, systemic glucocorticoids, or azathioprine.Previous biologic therapy; or inadequate response to at least one nonbiologic medication for Behcet's disease.
    StepRequired treatment or evaluationQualifying pathway
    1High-potency topical corticosteroid therapy for immunotherapy-related psoriasis or psoriasiform disease.For moderate to severe psoriasis or psoriasiform disease: inadequate response, intolerance, or contraindication to high-potency topical corticosteroids. Alternatively, moderate or severe immunotherapy-related inflammatory arthritis with symptoms suggestive of psoriatic arthritis or spondyloarthropathies qualifies.
    Policy Summary
    PayerCVS Caremark
    PolicySpecialty Guideline Management Otezla-Otezla XR
    Policy CodePolicy 2002-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit chart notes, medical record documentation, or claims history supporting previous medications tried for initial requests.
    SourceLink
    On This Page
    Coverage CriteriaAge and Product RequirementsProvider Requirements and Authorization GuidancePolicy BackgroundInitial Therapy by IndicationContinuation Therapy by IndicationStep Therapy Requirements
    Moderate or severe disease
    Applicable indicationsModerate to severe plaque psoriasis and active psoriatic arthritis
    Otezla XR pediatric weight requirement
    Minimum age6 years of age and older
    Minimum body weightAt least 50 kg
    Applicable indicationsModerate to severe plaque psoriasis and active psoriatic arthritis
  1. Document improvement from baseline in one or more of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin or nail involvement, functional status, or C-reactive protein (CRP).
  2. Prior Authorization

    Behcet's Disease Continuation

    For Behcet's disease, authorization for 12 months may be granted to adult members, including new members, who achieve or maintain a positive clinical response evidenced by low disease activity or improvement in signs and symptoms.

    Prior Authorization

    Immune Checkpoint Inhibitor-Related Toxicity Continuation

    For immune checkpoint inhibitor-related toxicity, authorization for 12 months may be granted to members, including new members, who use the requested medication for the covered toxicity and achieve or maintain a positive clinical response evidenced by low disease activity or improvement in signs and symptoms.

    • Applicable conditions include immunotherapy-related psoriasis or psoriasiform diseases and immunotherapy-related inflammatory arthritis suggestive of psoriatic arthritis or spondyloarthropathies.
    Billing Rule

    Dosing Limits May Apply

    Approvals may be subject to dosing limits consistent with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

    Prior Authorization

    Prior Authorization Submission

    Submit the required clinical information to initiate prior authorization review.

    • Submission of supporting documentation is necessary to initiate the prior authorization review.
    Documentation Required

    Initial-Treatment History

    For initial requests, provide documentation of prior medications tried and the member's treatment history, including response when applicable. If a therapy was not advisable, document the clinical reason it was avoided.

    • Plaque psoriasis and immune checkpoint inhibitor-related toxicity: chart notes, medical records, or claims history supporting previous medications tried, if applicable, and response to therapy.
    • Psoriatic arthritis: chart notes, medical records, or claims history supporting previous medications tried, if applicable, and response to therapy.
    • Behcet's disease: chart notes, medical records, or claims history supporting previous medications tried, including response when applicable.
    Documentation Required

    Continuation Response Documentation

    For continuation requests, submit clinical documentation demonstrating improvement or a positive response to treatment.

    • Plaque psoriasis and immune checkpoint inhibitor-related toxicity: chart notes or medical records documenting improvement in signs and symptoms.
    • Psoriatic arthritis: chart notes or medical records documenting a positive clinical response.
    Documentation Required

    Clinical Response Documentation

    Clinical response documentation must support the requested indication and the applicable member eligibility requirements for continuation authorization.

    • Psoriatic arthritis: member is age 6 years or older and has low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one specified disease measure.
    • Behcet's disease: member is an adult and has low disease activity or improvement in signs and symptoms.
    • Immune checkpoint inhibitor-related toxicity: member has a positive clinical response for immunotherapy-related psoriasis or psoriasiform disease, or inflammatory arthritis suggestive of psoriatic arthritis or spondyloarthropathies.
    Denial Risk

    Unlisted Indications

    Requests for indications outside the listed FDA-approved or compendial uses are considered experimental or investigational and are not medically necessary.

    • Compendial use includes immune checkpoint inhibitor-related toxicity.
    • All other unlisted indications are considered experimental/investigational and not medically necessary.
    Denial Risk

    Prohibited Concomitant Therapy

    The member cannot use the requested medication concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Concomitant same-indication biologic or targeted synthetic drug therapy may result in denial.
  3. Clinical reason to avoid methotrexate, cyclosporine, and acitretin.
  4. Psoriatic Arthritis — Initial Therapy Indication

    The psoriatic arthritis initial-therapy indication branch applies when the member has active disease, meets the age requirement, and satisfies at least one qualifying pathway.

    Psoriatic arthritis indication branch

    • Qualifying pathway

      • Previous biologic or targeted synthetic drug indicated for active psoriatic arthritis.
      • Inadequate response to methotrexate, leflunomide, or another conventional synthetic drug administered at an adequate dose and duration.
      • Intolerance or contraindication to methotrexate, leflunomide, or another conventional synthetic drug.
      • Enthesitis.

    Behcet's Disease — Initial Therapy Indication

    The Behcet's disease initial-therapy indication branch applies to adults with oral ulcers associated with Behcet's disease who meet at least one qualifying treatment pathway.

    Behcet's disease indication branch

    • Qualifying pathway

      • Previous biologic indicated for treatment of Behcet's disease.
      • Inadequate response to at least one nonbiologic medication for Behcet's disease.At least 1 nonbiologic medication

    Immune Checkpoint Inhibitor-Related Toxicity — Initial Therapy Indication

    The immune checkpoint inhibitor-related toxicity indication branch applies when the member has one qualifying immunotherapy-related condition and meets the applicable treatment pathway.

    Immune checkpoint inhibitor-related toxicity indication branch

    • Qualifying condition and pathway

      • Moderate to severe immunotherapy-related psoriasis or psoriasiform disease with inadequate response to high-potency topical corticosteroids.Moderate to severe disease
      • Moderate to severe immunotherapy-related psoriasis or psoriasiform disease with intolerance or contraindication to high-potency topical corticosteroids.Moderate to severe disease
      • Moderate or severe immunotherapy-related inflammatory arthritis with symptoms suggestive of psoriatic arthritis or spondyloarthropathies.Moderate or severe disease
    • Improvement from baseline in at least one of the following: number of swollen joints, number of tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement, functional status, or C-reactive protein.Improvement from baseline in >= 1 measure

    Behcet's Disease — Continuation Therapy Criteria

    Continuation authorization may be granted when the adult member meets all of the following criteria.

    Behcet's disease continuation

    • Response evidence

      • Low disease activity or improvement in signs and symptoms of Behcet's disease.Low disease activity or improvement in signs and symptoms

    Psoriatic Arthritis — 12-Month Authorization Criteria

    Authorization for 12 months may be granted when all required conditions are met.

    12-month authorization criteria: Member is age 6 years or older, including a new member; uses the requested medication for psoriatic arthritis; and achieves or maintains a positive clinical response evidenced by low disease activity or improvement in signs and symptoms, with improvement from baseline in at least one specified measure.Age >= 6 years; authorization period = 12 months; improvement in >= 1 measure

    Specified measures include swollen joints, tender joints, dactylitis, enthesitis, axial disease, skin and/or nail involvement, functional status, and C-reactive protein.

    Behcet's Disease — 12-Month Authorization Criteria

    Authorization for 12 months may be granted when all required conditions are met.

    12-month authorization criteria: Member is an adult, including a new member, and achieves or maintains a positive clinical response to the requested medication for Behcet's disease, evidenced by low disease activity or improvement in signs and symptoms.Adult member; authorization period = 12 months

    Immune Checkpoint Inhibitor-Related Toxicity — 12-Month Authorization Criteria

    Authorization for 12 months may be granted when all required conditions are met.

    12-month authorization criteria

    • Covered condition and response

      • Low disease activity or improvement in signs and symptoms of immunotherapy-related psoriasis or psoriasiform diseases.
      • Low disease activity or improvement in signs and symptoms of immunotherapy-related inflammatory arthritis suggestive of psoriatic arthritis or spondyloarthropathies.